Altogether, our data show that continuous in situ delivery of bsAb CD33–CD3 by genetically modified hMSCs represents a promising alternative to the exogenous administration of short-lived immunoagents for the antigen-specific immunotherapy of AML patients. The gene discussed is CD33; the disease is acute myeloid leukemia.